Biotechnology cancer Pharmaceuticals Prodrug

New Drug Combo Improves Survival of Women with Rare Uterine Cancer

Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value. The results of the trial, published online ahead of print on March 27 in the